APHP, Hôpitaux Universitaires Paris Centre, Infectious Diseases Federation, Paris, France.
Paris Descartes University, Paris, France.
Hepatology. 2019 Sep;70(3):939-954. doi: 10.1002/hep.30400. Epub 2019 Mar 15.
It is widely accepted that human immunodeficiency virus (HIV) infection is a risk factor for increased severity of hepatitis C virus (HCV) liver disease. However, owing to better efficacy and safety of combination antiretroviral therapy (cART), and increased access to HCV therapy, whether this condition remains true is still unknown. Overall, 1,253 HCV mono-infected patients and 175 HIV/HCV co-infected patients with cirrhosis, included in two prospective French national cohorts (ANRS CO12 CirVir and CO13 HEPAVIH), were studied. Cirrhosis was compensated (Child-Pugh A), without past history of complication, and assessed on liver biopsy. Incidences of liver decompensation (LD), hepatocellular carcinoma (HCC), and death according to HIV status were calculated by a Fine-Gray model adjusted for age. Propensity score matching was also performed to minimize confounding by baseline characteristics. At baseline, HIV/HCV patients were younger (47.5 vs. 56.0 years; P < 0.001), more frequently males (77.1% vs. 62.3%; P < 0.001), and had at baseline and at end of follow-up similar rates of HCV eradication than HCV mono-infected patients. A total of 80.4% of HIV/HCV patients had an undetectable HIV viral load. After adjustment for age, 5-year cumulative incidences of HCC and decompensation were similar in HIV/HCV and HCV patients (8.5% vs. 13.2%, P = 0.12 and 12.8% vs. 15.6%, P = 0.40, respectively). Overall mortality adjusted for age was higher in HIV/HCV co-infected patients (subhazard ratio [SHR] = 1.88; 95% confidence interval [CI], 1.15-3.06; P = 0.011). Factors associated with LD and HCC were age, absence of sustained virological response, and severity of cirrhosis, but not HIV status. Using a propensity score matching 95 patients of each group according to baseline features, similar results were observed. Conclusion: In HCV-infected patients with cirrhosis, HIV co-infection was no longer associated with higher risks of HCC and hepatic decompensation. Increased mortality, however, persisted, attributed to extrahepatic conditions.
人们普遍认为,人类免疫缺陷病毒(HIV)感染是丙型肝炎病毒(HCV)肝脏疾病严重程度增加的一个危险因素。然而,由于联合抗逆转录病毒疗法(cART)的疗效和安全性更好,以及获得 HCV 治疗的机会增加,这种情况是否仍然存在尚不清楚。总体而言,两项前瞻性法国国家队列研究(ANRS CO12 CirVir 和 CO13 HEPAVIH)纳入了 1253 例 HCV 单一感染患者和 175 例 HIV/HCV 合并感染伴肝硬化患者。肝硬化代偿良好(Child-Pugh A),无既往并发症史,通过肝活检评估。根据 HIV 状态计算肝失代偿(LD)、肝细胞癌(HCC)和死亡的发生率,采用 Fine-Gray 模型进行调整,以消除年龄的混杂因素。还进行了倾向评分匹配,以最大限度地减少基线特征的混杂。基线时,HIV/HCV 患者年龄较小(47.5 岁比 56.0 岁;P < 0.001),男性比例较高(77.1%比 62.3%;P < 0.001),且与 HCV 单一感染患者相比,基线和随访结束时 HCV 清除率相似。80.4%的 HIV/HCV 患者 HIV 病毒载量不可检测。在调整年龄后,HIV/HCV 和 HCV 患者 5 年 HCC 和失代偿的累积发生率相似(8.5%比 13.2%,P = 0.12 和 12.8%比 15.6%,P = 0.40)。经年龄调整的总死亡率在 HIV/HCV 合并感染患者中较高(亚危险比[SHR] = 1.88;95%置信区间[CI],1.15-3.06;P = 0.011)。LD 和 HCC 的相关因素是年龄、无持续病毒学应答和肝硬化严重程度,但与 HIV 状态无关。根据基线特征对每组 95 名患者进行倾向评分匹配后,观察到了类似的结果。结论:在 HCV 感染伴肝硬化的患者中,HIV 合并感染与 HCC 和肝失代偿的风险增加不再相关。然而,由于肝外因素,死亡率增加仍然存在。